Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ViroVet logo — Please follow us on X (@ViroVet) or check our website for ne...

ViroVet

Please follow us on X (@ViroVet) or check our website for news about ViroVet

Founded 2015 Belgium Belgium 11 employees Series B Total: $6.00M Biotechnology, Pharmaceutical

General Information

Company Name ViroVet
Founded Year 2015
Location Belgium Belgium
Employees 11
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with ViroVet. To contact ViroVet, visit virovet.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ViroVet compare?

A PDF of ViroVet and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ViroVet soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ViroVet

ViroVet, founded in 2015 and headquartered in Belgium, is a pioneering player in the Biotechnology and Pharmaceutical industries. The company targets the livestock sector, addressing the pressing challenge of fast-spreading viral diseases. By leveraging a dedicated team of researchers and a robust network of academic and industrial partners, ViroVet is at the forefront of delivering innovative virus control solutions. These advancements are crucial for enhancing the health and economic value of livestock globally.

In its growth journey, ViroVet secured a €6.00M Series B investment on 28 May 2020. This round saw participation from notable investors such as Capricorn Venture Partners, Seventure Partners, PMV, the Agri Investment Fund, Gemma Frisius Fund, Fonds Vives II (University of Louvain, UCL), Biotech Fund Flanders, and KU Leuven. This financial backing underscored investor confidence in ViroVet's potential to transform livestock health management.

Business keywords: viral disease control, antiviral drugs, innovative vaccines, livestock industry, viral infections, respiratory disease complexes, swine diseases, animal health, protein supply security, biosecurity measures, disruptive technology, livestock medicine, veterinary pharmaceuticals, antibiotic reduction, global trade implications

Services & Products

Development of antiviral drugs for livestock
Creation of innovative vaccines for viral diseases

Target Customers

Livestock farmers Veterinary professionals Animal health companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €6.00M 8
Capricorn Venture Partners Seventure Partners PMV
Capricorn Venture Partners, Seventure Partners +6
28 May 2020
Series A Undisclosed 1
Capricorn Venture Partners
Capricorn Venture Partners
06 Oct 2017

ViroVet Alternatives & Competitors

View All Alternatives
ViroVet vs
Sciwind Biosciences
Sciwind Biosciences

Pioneering treatments to empower physicians in addressing metabolic disorders with advanced protein...

Series C
1 employees
Biotechnology, Health Care
ViroVet vs
Glyscend Therapeutics
Glyscend Therapeutics United States

Advancing a new class of oral gut-targeted polymeric drugs for the treatment of T2D and Obesity

Series A
5 employees
Biopharma, Biotechnology
ViroVet vs
Innovac Therapeutics
Innovac Therapeutics United States

Bring Innovative mRNA Vaccines to Life

Seed
14 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About ViroVet

Please follow us on X (@ViroVet) or check our website for news about ViroVet
ViroVet was founded in 2015.
ViroVet is headquartered in Belgium.
ViroVet operates in Biotechnology and Pharmaceutical. Its work centres on viral disease control, antiviral drugs, innovative vaccines and livestock industry. Its customers include Livestock farmers, Veterinary professionals and Animal health companies.
ViroVet has a B2B and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
ViroVet has approximately 11 employees.
ViroVet has completed 2 funding rounds, raising a total of $6.00M. The latest funding stage is Series B.
ViroVet offers: Development of antiviral drugs for livestock, Creation of innovative vaccines for viral diseases.
Top alternatives and competitors to ViroVet include Sciwind Biosciences, Glyscend Therapeutics, Innovac Therapeutics, Ziphius, Upstream Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ViroVet and Sciwind Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ViroVet, https://bouncewatch.com/company/virovet, updated 17 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout